— Know what they know.
Not Investment Advice

RIGL NASDAQ

Rigel Pharmaceuticals, Inc.
1W: -8.6% 1M: -4.2% 3M: -17.7% YTD: -30.2% 1Y: +45.1% 3Y: +126.3% 5Y: -21.3%
$29.01
-0.18 (-0.62%)
 
Weekly Expected Move ±10.6%
$23 $26 $29 $32 $35
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 55 · $536.7M mcap · 18M float · 2.23% daily turnover · Short 58% of daily vol

Balance Sheet Trends

Total Assets
$514M +213.2% ▲
5Y CAGR: +36.0%
Total Liabilities
$122M -24.0% ▼
5Y CAGR: +9.8%
Shareholders Equity
$391M +11806.3% ▲
5Y CAGR: +63.0%
Cash & Investments
$155M +100.4% ▲
5Y CAGR: +22.0%
Total Debt
$53M -11.1% ▼
5Y CAGR: +6.4%
Net Debt
$13M +295.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$19M$24M$33M$57M$41M
Short-Term Investments$106M$34M$24M$21M$114M
Cash & ST Investments$125M$58M$57M$77M$155M
Net Receivables$15M$40M$31M$42M$52M
Inventory$7M$9M$6M$6M$12M
Other Current Assets$0$8M$6M$10M$22M
Total Current Assets$154M$116M$99M$135M$240M
Property, Plant & Equip.$12M$3M$1M$338K$920K
Goodwill & Intangibles$0$15M$14M$27M$25M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$974K$640K$3M$1M$2M
Total Non-Current Assets$13M$18M$18M$29M$273M
Total Assets$167M$134M$117M$164M$514M
— Liabilities —
Accounts Payable$4M$23M$7M$3M$7M
Short-Term Debt$0$0$7M$7M$30M
Deferred Revenue$11M$14M$17M$28M$0
Other Current Liabilities$24M$14M$12M$10M$62M
Total Current Liabilities$64M$65M$53M$63M$99M
Long-Term Debt$20M$39M$52M$52M$23M
Other Non-Current Liab.$53M$42M$40M$45M$0
Total Non-Current Liabilities$73M$83M$93M$97M$23M
Total Liabilities$137M$148M$146M$161M$122M
— Equity —
Common Stock$172K$174K$17K$18K$18K
Retained Earnings-$1.3B-$1.4B-$1.4B-$1.4B-$1.0B
Accumulated OCI-$102K-$153K$8K$10K$181K
Total Stockholders Equity$30M-$14M-$29M$3M$391M
Total Liabilities & Equity$167M$134M$117M$164M$514M
— Key Metrics —
Total Debt$31M$42M$61M$60M$53M
Net Debt$12M$17M$28M$3M$13M
Total Investments$106M$34M$24M$21M$114M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms